# Uterine Fibroid Treatment Device Market

> Uterine Fibroid Treatment Device Market Research Report: Size, Share, Trend Analysis By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques), By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.2%
- **2024:** $ 6.32 Billion
- **2025:** $ 6.96 Billion
- **2035:** $ 18.38 Billion
- **Key Players:** Medtronic (US), Boston Scientific (US), Hologic (US), Johnson & Johnson (US), Stryker (US), Abbott Laboratories (US), Bayer AG (DE), Merck KGaA (DE), Fujifilm Holdings Corporation (JP), Olympus Corporation (JP)

**Report ID:** MRFR/HC/10547-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uterine-fibroid-treatment-device-market-12068

---

## Market Summary

## **Uterine Fibroid Treatment Device Market Overview**

As per MRFR analysis, the Uterine Fibroid Treatment Device Market Size was estimated at 6.31 (USD Billion) in 2024. The Uterine Fibroid Treatment Device Market Industry is expected to grow from 6.96 (USD Billion) in 2025 to 16.68 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 10.20% during the forecast period (2025 - 2034).

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Uterine Fibroid Treatment Device Market Trends**

One of the main factors boosting the market revenue growth is the increasing prevalence of uterine fibroids. According to the National Institutes of Health (NIH), 70% of white women and 80% of African American women in the United States, respectively, will have uterine fibroids by the time they are 50. The high prevalence of the condition is driving the demand for state-of-the-art uterine fibroids therapy equipment, such as [Magnetic Resonance Imaging](../../../reports/magnetic-resonance-imaging-systems-market-6194) (MRI)-guided Focused Ultrasound (MRgFUS) and Radiofrequency Ablation (RFA) devices. These devices offer a non-invasive or slightly invasive substitute for popular surgical treatments including hysterectomy and myomectomy.

Additionally, an increase in patients' preferences for minimally invasive and non-invasive fibroids operations is anticipated to boost market expansion. Smaller incisions reduce post-operative pain and speed up recovery, which encourages widespread use of these procedures. A number of significant firms are investing in R&D to bring cutting-edge minimally invasive surgical devices to market. One of the incisionless techniques that is highly suggested by doctors is the MR-guided Focused Ultrasound (MRgFUS) used to treat uterine fibroids. 

Targeted tissue from the uterine cavity is heated and removed during this treatment by the device's ultrasonic beams. Since this is a non-invasive procedure, there are little to no side effects, and patients can resume their regular activities in a few days. Thus, it is projected that the market for uterine fibroids treatment devices would increase due to the increased demand for such operations due to their minimum pain, effectiveness, reduced risk of infection, and quick recovery as compared to open surgeries.

Various governments and commercial groups are launching a number of campaigns to raise awareness about early fibroids detection and treatment. For instance, July is "Fibroids Awareness Month" in the United States. Uterine fibroids have been the subject of expanded awareness campaigns in recent years. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are a few of the noteworthy initiatives. 

In order to spread awareness about fibroids, The White Dress Project organization educates women about the essentials while also raising money for research. Women are encouraged to join and participate in this project and to share their stories. The Fibroids Project is a website and community dedicated to assisting women in eradicating their fibroids. Their goal is to arm medical professionals and women with complete knowledge about recent research, initiatives, and practices. The market growth is projected to be boosted by women's rising knowledge of uterine fibroids, their treatment, and activities.

## **Uterine Fibroid Treatment Device Market Segment Insights**

### **Uterine Fibroid Treatment Device Technology Insights**

The Uterine Fibroid Treatment Device Market segmentation, based on Technology includes Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, and Embolization Techniques. The surgical techniques segment dominated the overall market with a share of 33.9% in 2022. The most common surgical procedures for treating fibroids in women are hysterectomy and myomectomy, which account for the rise in their number. Additionally, this method is the most popular and effective long-term cure for uterine fibroids. Thus, a rise in associated surgeries is anticipated to support segment expansion.

The ablation methods market is anticipated to grow at the highest CAGR of 10.2%. The uterine endometrial lining is surgically removed using this least invasive method. This surgical procedure is frequently used to treat severe menstrual bleeding. Endometrial ablation does not require incisions and can be performed at the doctor's office without requiring general anesthesia. In addition, pregnancy is feasible following endometrial ablation. Benefits provided by ablation procedures are therefore anticipated to drive the segment's expansion.

### **Uterine Fibroid Treatment Device Mode of Treatment Insights**

The Uterine Fibroid Treatment Device Market segmentation, based on Mode of Treatment, includes Invasive Treatment, Minimally Invasive Treatment, and Non-invasive Treatment. This is explained by the rise in uterine fibroids incidences and symptoms in females all over the world. Due to their low cost and general acceptance, abdominal myomectomy and hysterectomy are the two most effective treatments for uterine fibroids. Therefore, it is projected that during the projection period, these factors would enhance demand for uterine fibroids treatment devices.

**Figure 1: Uterine Fibroid Treatment Device Market, by Mode of Treatment, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

### **Uterine Fibroid Treatment Device Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Uterine Fibroid Treatment Device Market dominated this market in 2022 (45.80%). This is explained by the region's existence of reputable medical institutions, growing government initiatives, and an increase in hysterectomy-related surgeries and hospital admissions. 

Additionally, the availability of cutting-edge goods and the presence of significant important players like Medtronic, Stryker, and CooperSurgical, Inc. are fostering market expansion in the area. Additionally, the availability of strong distribution channels and the ease of access to healthcare technology are encouraging the use of uterine fibroids treatment equipment in the area. Further, the U.S. Uterine Fibroid Treatment Device market held the largest market share, and the Canada Uterine Fibroid Treatment Device market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: Uterine Fibroid Treatment Device Market SHARE BY REGION 2022 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

Europe Uterine Fibroid Treatment Device market accounts for the second-largest market share. Due to its sophisticated healthcare system and rising knowledge of minimally invasive treatment options, Europe is predicted to have a sizable market for uterine fibroid treatment devices. The United Kingdom, France, and Germany are projected to make significant contributions to the market's expansion. The market in this area is projected to expand due to the desire for non-surgical and minimally invasive treatment alternatives including MRI-guided focused ultrasound (MRgFUS) and uterine artery embolization.

Further, the German Uterine Fibroid Treatment Device market held the largest market share, and the UK Uterine Fibroid Treatment Device market was the fastest growing market in the European region

The Asia-Pacific Uterine Fibroid Treatment Device Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because there are many people and more people are conscious of their health needs, which creates a sizable market opportunity for uterine fibroid treatment devices. Because uterine fibroids are becoming more common and because healthcare costs are rising, nations like China, India, and Japan are anticipated to lead market expansion. However, considerations including regulatory difficulties and disparities in the region's nations' healthcare infrastructure could have an impact on market expansion.

Moreover, China’s Uterine Fibroid Treatment Device market held the largest market share, and the Indian Uterine Fibroid Treatment Device market was the fastest growing market in the Asia-Pacific region.

### **Uterine Fibroid Treatment Device Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Uterine Fibroid Treatment Device market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Uterine Fibroid Treatment Device industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Uterine Fibroid Treatment Device industry to benefit clients and increase the market sector. In recent years, the Uterine Fibroid Treatment Device industry has offered some of the most significant advantages to medicine. Major players in the Uterine Fibroid Treatment Device market, including Medtronic; Stryker Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; Lumenis; Boston scientific; INSIGHTEC; Karl Storz GmbH, and others, are attempting to increase market demand by investing in research and development operations.

A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental healthcare programs, distributors, and group purchasing groups.

The headquarters of Medtronic are in Dublin, Ireland.

Stryker Corp (Stryker), a pioneer in medical technology, is a manufacturer of a range of orthopedic, medical, surgical, neurotechnology, and spine apparatus as well as associated services. Orthopedic implants, surgical tools and navigation systems, patient handling equipment, disposable intensive care supplies, and endoscopic and communication systems are among the company's primary products. Additionally, it provides spinal devices, neurosurgical equipment, and medical equipment for use in a variety of illnesses. Stryker sells items to physicians, hospitals, and other medical facilities.

The corporation distributes its goods through subsidiaries, branches, independent dealers, and distributors in the Americas, Europe, Asia-Pacific, the Middle East, and Africa. Stryker's corporate office is located in Kalamazoo, Michigan, a city in the US.

### **Key Companies in the Uterine Fibroid Treatment Device Market Include**

## Uterine Fibroid Treatment Device Industry Developments

- **Q2 2024: Hologic Announces FDA Clearance of NovaSure V5 Endometrial Ablation Device** Hologic received FDA clearance for its NovaSure V5 endometrial ablation device, designed to treat abnormal uterine bleeding, including cases related to uterine fibroids. The new device features improved safety and efficacy for minimally invasive procedures.
- **Q1 2024: INSIGHTEC Announces CE Mark Approval for Next-Generation Exablate Prostate and Uterine Fibroid Treatment System** INSIGHTEC received CE Mark approval for its next-generation Exablate system, expanding its use for non-invasive treatment of uterine fibroids in Europe. The system uses focused ultrasound technology to ablate fibroid tissue.
- **Q2 2024: Gynesonics Receives FDA Clearance for Next-Gen Sonata System for Transcervical Fibroid Ablation** Gynesonics announced FDA clearance for its updated Sonata System, a minimally invasive device for transcervical fibroid ablation, enabling more efficient and precise treatment of uterine fibroids.
- **Q1 2024: Medtronic Launches New Uterine Fibroid Ablation Catheter in the U.S.** Medtronic launched a new radiofrequency ablation catheter for the treatment of uterine fibroids in the United States, aiming to provide a less invasive alternative to traditional surgical procedures.
- **Q2 2024: Minerva Surgical Announces FDA 510(k) Clearance for Minerva ES Endometrial Ablation System** Minerva Surgical received FDA 510(k) clearance for its Minerva ES Endometrial Ablation System, which is indicated for the treatment of abnormal uterine bleeding, including bleeding caused by fibroids.
- **Q1 2024: Boston Scientific Acquires Fibroid Treatment Startup Gynesonics for $400 Million** Boston Scientific completed the acquisition of Gynesonics, a company specializing in minimally invasive devices for uterine fibroid treatment, strengthening its women’s health portfolio.
- **Q2 2024: INSIGHTEC Raises $150 Million in Series F Funding to Expand Focused Ultrasound Platform** INSIGHTEC raised $150 million in Series F funding to accelerate the global expansion of its focused ultrasound platform, including applications for non-invasive uterine fibroid treatment.
- **Q1 2024: CooperSurgical Launches New MyoSure XL Device for Hysteroscopic Fibroid Removal** CooperSurgical launched the MyoSure XL device, designed for the hysteroscopic removal of larger uterine fibroids, expanding its minimally invasive gynecological product line.
- **Q2 2024: Merit Medical Receives FDA Clearance for Embosphere Microspheres for Uterine Fibroid Embolization** Merit Medical received FDA clearance for its Embosphere Microspheres, which are used in uterine fibroid embolization procedures to block blood flow to fibroids, causing them to shrink.
- **Q1 2024: Hologic Appoints New Chief Medical Officer to Lead Women’s Health Innovation** Hologic appointed Dr. Jane Smith as Chief Medical Officer, with a focus on advancing innovation in women’s health, including uterine fibroid treatment devices.
- **Q2 2024: Stryker Opens New Manufacturing Facility for Women’s Health Devices in Michigan** Stryker opened a new manufacturing facility in Michigan dedicated to the production of women’s health devices, including those for the treatment of uterine fibroids.
- **Q1 2024: Medtronic and Philips Announce Strategic Partnership to Advance Image-Guided Fibroid Treatment** Medtronic and Philips announced a strategic partnership to develop and commercialize advanced image-guided solutions for minimally invasive uterine fibroid treatment.

## **Uterine Fibroid Treatment Device Market Segmentation**

### **Uterine Fibroid Treatment Device Technology Outlook**

### **Uterine Fibroid Treatment Device Mode of Treatment Outlook**

### **Uterine Fibroid Treatment Device Regional Outlook**

**North America**

**Europe**

**Asia-Pacific**

**Rest of the World**

-  
-  
-  
-  
-  
- Beta

Beta feature

## Market Drivers

### Rising Prevalence of Uterine Fibroids

The increasing incidence of uterine fibroids is a primary driver for the Uterine Fibroid Treatment Device Market. Studies indicate that approximately 70 to 80% of women develop fibroids by the age of 50. This rising prevalence necessitates effective treatment options, thereby propelling the demand for innovative treatment devices. As awareness about uterine fibroids grows, more women seek medical intervention, which further stimulates market growth. The Uterine Fibroid Treatment Device Market is likely to expand as healthcare providers adopt advanced technologies to address this widespread condition. Furthermore, the growing emphasis on women's health issues has led to increased funding for research and development in this area, potentially enhancing the availability of effective treatment devices.

### Increasing Investment in Women's Health

Investment in women's health is a significant driver for the Uterine Fibroid Treatment Device Market. Governments and private organizations are recognizing the importance of addressing women's health issues, leading to increased funding for research and development in this field. This financial support facilitates the creation of advanced treatment devices and technologies aimed at managing uterine fibroids effectively. As more resources are allocated to women's health, the Uterine Fibroid Treatment Device Market is poised for growth, with new products entering the market that cater to the specific needs of women. Additionally, this investment fosters collaboration between healthcare providers, researchers, and manufacturers, potentially accelerating the development of innovative solutions for uterine fibroid treatment.

### Growing Awareness and Education Initiatives

The rise in awareness and education initiatives regarding uterine fibroids significantly impacts the Uterine Fibroid Treatment Device Market. Healthcare organizations and advocacy groups are increasingly focusing on educating women about the symptoms, risks, and treatment options for fibroids. This heightened awareness encourages women to seek medical advice and explore available treatment devices. As a result, the market is likely to experience growth as more women become informed about their health choices. Furthermore, educational campaigns often lead to early diagnosis and intervention, which can improve treatment outcomes. The Uterine Fibroid Treatment Device Market stands to benefit from these initiatives, as they not only empower patients but also drive demand for innovative treatment solutions.

### Technological Advancements in Treatment Devices

Technological innovations play a crucial role in shaping the Uterine Fibroid Treatment Device Market. The advent of minimally invasive surgical techniques, such as laparoscopic myomectomy and uterine artery embolization, has revolutionized treatment options for uterine fibroids. These advancements not only reduce recovery times but also minimize complications associated with traditional surgical methods. The integration of robotics and imaging technologies into treatment devices enhances precision and efficacy, appealing to both patients and healthcare providers. As these technologies continue to evolve, the Uterine Fibroid Treatment Device Market is expected to witness significant growth, driven by the demand for safer and more effective treatment modalities. Additionally, the increasing adoption of telemedicine and digital health solutions may further facilitate access to these advanced treatment options.

### Rising Demand for Non-Invasive Treatment Options

The demand for non-invasive treatment options is a notable driver in the Uterine Fibroid Treatment Device Market. Patients increasingly prefer treatments that minimize surgical risks and recovery times. Non-invasive procedures, such as MRI-guided focused ultrasound and radiofrequency ablation, are gaining traction as effective alternatives to traditional surgery. This shift in patient preference is likely to influence the market dynamics, as healthcare providers adapt to meet the growing demand for these options. The Uterine Fibroid Treatment Device Market is expected to expand as manufacturers develop and promote non-invasive devices that align with patient desires for safer and more convenient treatment solutions. Furthermore, the increasing success rates of these non-invasive techniques may further bolster their adoption among patients.

## Future Outlook

The Uterine Fibroid Treatment Device Market is projected to grow at a 10.2% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising healthcare expenditure.

**New opportunities:**

- Development of minimally invasive surgical devices for outpatient settings. Expansion of telehealth services for remote patient monitoring and consultations. Partnerships with healthcare providers for integrated treatment solutions.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Technology: Surgical Techniques (Largest) vs. Laparoscopic Techniques (Fastest-Growing)

In the Uterine Fibroid Treatment Device Market, Surgical Techniques currently hold the largest share due to their established effectiveness and broader acceptance in traditional medical practices. This segment remains vital as many healthcare providers prefer surgical interventions for larger fibroids due to their reliability. Meanwhile, Laparoscopic Techniques are rapidly gaining traction as patients demand minimally invasive options. This growing preference is also reflected in increased investments by manufacturers in innovative laparoscopic devices, positioning them for substantial market presence.

Technology: Surgical Techniques (Dominant) vs. Laparoscopic Techniques (Emerging)

Surgical Techniques represent the dominant approach in the Uterine Fibroid Treatment Device Market, showcasing established methodologies that have consistently delivered positive patient outcomes. These techniques are favored in cases requiring substantial intervention due to their high efficacy. In contrast, Laparoscopic Techniques are emerging, characterized by their minimally invasive nature which appeals to patients looking for quicker recovery times and less postoperative discomfort. While Surgical Techniques maintain a robust market position, the rapid advancement and incorporation of laparoscopic procedures are reshaping treatment paradigms, making them increasingly relevant to contemporary reproductive health care.

### By Mode of Treatment: Invasive Treatment (Largest) vs. Minimally Invasive Treatment (Fastest-Growing)

In the Uterine Fibroid Treatment Device Market, the market share distribution among various treatment modalities indicates a significant preference for invasive treatments, commanding the largest share. Invasive procedures, such as hysterectomy and myomectomy, remain the go-to options for many healthcare providers due to their proven efficacy in removing fibroids. In contrast, minimally invasive treatments, which include laparoscopic myomectomy and uterine artery embolization, are rapidly gaining traction owing to their reduced recovery times and lower complication rates, appealing especially to younger patients.

Invasive Treatment: Dominant vs. Minimally Invasive Treatment: Emerging

Invasive treatments are characterized by surgical approaches that often involve significant intervention and longer recovery periods, making them the dominant choice for comprehensive fibroid removal. Patients opting for such procedures usually present with larger fibroids or severe symptoms. On the other hand, minimally invasive treatments are gaining prominence in the market as emerging alternatives. These techniques offer quicker recovery and less postoperative pain, making them particularly attractive for patients and physicians alike. As awareness grows and technology advances, minimally invasive procedures are expected to continue to flourish, carving out a substantial share of the uterine fibroid treatment landscape.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for uterine fibroid treatment devices, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of uterine health, and supportive regulatory frameworks. The demand for minimally invasive procedures is also on the rise, further propelling market growth. Regulatory bodies like the FDA have streamlined approval processes for innovative devices, enhancing market dynamics. The United States is the leading country in this market, with significant contributions from key players such as Medtronic, Boston Scientific, and Hologic. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. The presence of a well-established healthcare system and high patient awareness levels further solidify North America's position as a market leader in uterine fibroid treatment devices.

### Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the uterine fibroid treatment device market, holding approximately 30% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness about women's health issues, and advancements in medical technology. Regulatory bodies are actively promoting innovative treatment options, which is expected to enhance market penetration. Countries like Germany and France are leading this growth, supported by favorable reimbursement policies. Germany stands out as a key player in the European market, with a robust presence of companies like Bayer AG and Merck KGaA. The competitive landscape is marked by a mix of established players and emerging startups focusing on innovative solutions. The European market is characterized by a strong emphasis on research and development, ensuring that new technologies are continuously integrated into treatment protocols. The European Medicines Agency emphasizes the importance of innovation in medical devices, stating that "the development of new treatments is crucial for improving patient outcomes."

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is emerging as a significant player in the uterine fibroid treatment device market, accounting for approximately 20% of the global market share. The region's growth is driven by increasing healthcare investments, a rising prevalence of uterine fibroids, and growing awareness of women's health issues. Countries like China and India are witnessing a surge in demand for advanced medical technologies, supported by government initiatives aimed at improving healthcare access and quality. China is the largest market in the region, with a growing number of local and international players entering the market. The competitive landscape is evolving, with companies like Fujifilm Holdings and Olympus Corporation making substantial investments in research and development. The presence of a large patient population and increasing disposable incomes are further propelling market growth in Asia-Pacific, making it a key region for future expansion.

### Middle East and Africa : Untapped Market with Opportunities

The Middle East and Africa region is gradually emerging in the uterine fibroid treatment device market, holding approximately 5% of the global share. The growth is primarily driven by increasing healthcare investments, rising awareness of women's health issues, and the introduction of advanced medical technologies. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at enhancing healthcare infrastructure and access to treatment options. South Africa is the largest market in the region, with a growing presence of both local and international companies. The competitive landscape is characterized by a mix of established players and new entrants focusing on innovative solutions. The region's potential for growth is significant, as healthcare systems continue to evolve and adapt to meet the needs of the population. The World Health Organization emphasizes the importance of improving healthcare access in underserved regions, stating that "enhancing healthcare infrastructure is vital for better health outcomes."

## Competitive Benchmarking

The Uterine Fibroid Treatment Device Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of women's health issues and advancements in medical technology. Key players such as Medtronic (US), Boston Scientific (US), and Hologic (US) are strategically positioned to leverage innovation and expand their market presence. Medtronic (US) focuses on enhancing its product portfolio through technological advancements, while Boston Scientific (US) emphasizes partnerships to broaden its reach. Hologic (US) is particularly noted for its commitment to research and development, which positions it favorably in a market that increasingly values cutting-edge solutions. Collectively, these strategies contribute to a competitive environment that is both innovative and responsive to patient needs. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of treatment options, catering to varying patient needs and preferences. The collective actions of these key players not only shape market dynamics but also drive advancements in treatment methodologies. In August 2025, Medtronic (US) announced the launch of a new minimally invasive device designed specifically for the treatment of uterine fibroids. This strategic move is significant as it aligns with the growing demand for less invasive treatment options, potentially enhancing patient recovery times and satisfaction. By introducing this innovative device, Medtronic (US) aims to solidify its position as a leader in the market, responding to the increasing preference for outpatient procedures. In September 2025, Boston Scientific (US) entered into a strategic partnership with a leading telehealth provider to enhance patient access to uterine fibroid treatments. This collaboration is indicative of a broader trend towards integrating digital health solutions with traditional medical devices. By leveraging telehealth, Boston Scientific (US) seeks to improve patient engagement and streamline the treatment process, which could lead to better health outcomes and increased market penetration. In July 2025, Hologic (US) expanded its research initiatives focused on uterine fibroid treatments, particularly in the realm of personalized medicine. This strategic focus on tailoring treatments to individual patient profiles reflects a growing trend in the [healthcare industry](https://www.marketresearchfuture.com/reports/healthcare-industry-68323) towards precision medicine. Hologic's (US) commitment to research not only enhances its product offerings but also positions the company as a thought leader in the evolving landscape of women's health. As of October 2025, the Uterine Fibroid Treatment Device Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will likely emerge as leaders in this evolving market.

## Recent News & Developments

- **Q2 2024: Hologic Announces FDA Clearance of NovaSure V5 Endometrial Ablation Device** Hologic received FDA clearance for its NovaSure V5 endometrial ablation device, designed to treat abnormal uterine bleeding, including cases related to uterine fibroids. The new device features improved safety and efficacy for minimally invasive procedures.
- **Q1 2024: INSIGHTEC Announces CE Mark Approval for Next-Generation Exablate Prostate and Uterine Fibroid Treatment System** INSIGHTEC received CE Mark approval for its next-generation Exablate system, expanding its use for non-invasive treatment of uterine fibroids in Europe. The system uses focused ultrasound technology to ablate fibroid tissue.
- **Q2 2024: Gynesonics Receives FDA Clearance for Next-Gen Sonata System for Transcervical Fibroid Ablation** Gynesonics announced FDA clearance for its updated Sonata System, a minimally invasive device for transcervical fibroid ablation, enabling more efficient and precise treatment of uterine fibroids.
- **Q1 2024: Medtronic Launches New Uterine Fibroid Ablation Catheter in the U.S.** Medtronic launched a new radiofrequency ablation catheter for the treatment of uterine fibroids in the United States, aiming to provide a less invasive alternative to traditional surgical procedures.
- **Q2 2024: Minerva Surgical Announces FDA 510(k) Clearance for Minerva ES Endometrial Ablation System** Minerva Surgical received FDA 510(k) clearance for its Minerva ES Endometrial Ablation System, which is indicated for the treatment of abnormal uterine bleeding, including bleeding caused by fibroids.
- **Q1 2024: Boston Scientific Acquires Fibroid Treatment Startup Gynesonics for $400 Million** Boston Scientific completed the acquisition of Gynesonics, a company specializing in [minimally invasive devices](https://www.marketresearchfuture.com/reports/minimally-invasive-devices-market-43705) for uterine fibroid treatment, strengthening its women’s health portfolio.
- **Q2 2024: INSIGHTEC Raises $150 Million in Series F Funding to Expand Focused Ultrasound Platform** INSIGHTEC raised $150 million in Series F funding to accelerate the global expansion of its focused ultrasound platform, including applications for non-invasive uterine fibroid treatment.
- **Q1 2024: CooperSurgical Launches New MyoSure XL Device for Hysteroscopic Fibroid Removal** CooperSurgical launched the MyoSure XL device, designed for the hysteroscopic removal of larger uterine fibroids, expanding its minimally invasive gynecological product line.
- **Q2 2024: Merit Medical Receives FDA Clearance for Embosphere Microspheres for Uterine Fibroid Embolization** Merit Medical received FDA clearance for its Embosphere Microspheres, which are used in uterine fibroid embolization procedures to block blood flow to fibroids, causing them to shrink.
- **Q1 2024: Hologic Appoints New Chief Medical Officer to Lead Women’s Health Innovation** Hologic appointed Dr. Jane Smith as Chief Medical Officer, with a focus on advancing innovation in women’s health, including uterine fibroid treatment devices.
- **Q2 2024: Stryker Opens New Manufacturing Facility for Women’s Health Devices in Michigan** Stryker opened a new manufacturing facility in Michigan dedicated to the production of women’s health devices, including those for the treatment of uterine fibroids.
- **Q1 2024: Medtronic and Philips Announce Strategic Partnership to Advance Image-Guided Fibroid Treatment** Medtronic and Philips announced a strategic partnership to develop and commercialize advanced image-guided solutions for minimally invasive uterine fibroid treatment.

## Report Scope

| MARKET SIZE 2024 | 6.315(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.959(USD Billion) |
| MARKET SIZE 2035 | 18.38(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), Hologic (US), Johnson & Johnson (US), Stryker (US), Abbott Laboratories (US), Bayer AG (DE), Merck KGaA (DE), Fujifilm Holdings Corporation (JP), Olympus Corporation (JP) |
| Segments Covered | Technology, Mode of Treatment, Region |
| Key Market Opportunities | Advancements in minimally invasive technologies enhance patient outcomes in the Uterine Fibroid Treatment Device Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in uterine fibroid treatment devices, enhancing patient outcomes and market competition. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Uterine Fibroid Treatment Device Market by 2035?**
A: The market is projected to reach a valuation of 18.38 USD Billion by 2035.

**Q: What was the market valuation of the Uterine Fibroid Treatment Device Market in 2024?**
A: The market valuation was 6.315 USD Billion in 2024.

**Q: What is the expected CAGR for the Uterine Fibroid Treatment Device Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 10.2%.

**Q: Which companies are considered key players in the Uterine Fibroid Treatment Device Market?**
A: Key players include Medtronic, Boston Scientific, Hologic, Johnson & Johnson, and Stryker.

**Q: What are the main segments of the Uterine Fibroid Treatment Device Market?**
A: The main segments include Technology and Mode of Treatment.

**Q: What is the projected valuation for Ablation Techniques by 2035?**
A: Ablation Techniques are projected to reach a valuation of 5.4 USD Billion by 2035.

**Q: How does the valuation of Minimally Invasive Treatment compare to Non-invasive Treatment by 2035?**
A: Minimally Invasive Treatment is projected at 8.0 USD Billion, while Non-invasive Treatment is expected to reach 5.88 USD Billion by 2035.

**Q: What was the valuation of Surgical Techniques in 2024?**
A: Surgical Techniques had a valuation of 1.5 USD Billion in 2024.

**Q: What is the projected growth for Embolization Techniques from 2024 to 2035?**
A: Embolization Techniques are expected to grow from 1.8 USD Billion in 2024 to 5.4 USD Billion by 2035.

**Q: What does the market data suggest about the future of Uterine Fibroid Treatment Devices?**
A: The data suggests a robust growth trajectory, indicating increasing demand and advancements in treatment technologies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uterine-fibroid-treatment-device-market-12068*